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Abstract. Salinomycin is a monocarboxylic polyether anti-
biotic, which is widely used as an anticoccidial agent. The 
anticancer property of salinomycin has been recognized and 
is based on its ability to induce apoptosis in human multidrug 
resistance (MDR). The present study investigated whether 
salinomycin reverses MDR towards chemotherapeutic agents 
in doxorubicin-resistant MCF-7/MDR human breast cancer 
cells. The results demonstrated that doxorubicin-mediated 
cytotoxicity was significantly enhanced by salinomycin in 
the MCF-7/MDR cells, and this occurred in a dose-dependent 
manner. This finding was consistent with subsequent obser-
vations made under a confocal microscope, in which the 
doxorubicin fluorescence signals of the salinomycin‑treated 
cells were higher compared with the cells treated with 
doxorubicin alone. In addition, flow cytometric analysis 
revealed that salinomycin significantly increased the net 
cellular uptake and decreased the efflux of doxorubicin. The 
expression levels of MDR-1 and MRP-1 were not altered at 
either the mRNA or protein levels in the cells treated with 
salinomycin. These results indicated that salinomycin was 
mediated by its ability to increase the uptake and decrease 
the efflux of doxorubicin in MCF‑7/MDR cells. Salinomycin 
reversed the resistance of doxorubicin, suggesting that 
chemotherapy in combination with salinomycin may benefit 
MDR cancer therapy.
Introduction
Breast cancer is one of the most frequently diagnosed types 
of cancer in females (1). The risk factors for breast cancer 
are age, alcohol consumption, body mass index, hormone 
replacement therapy and reproductive factors (2). The majority 
of females with breast cancer develop metastasis in common 
sites, including the bone, liver and lung (3). Several reports 
have revealed that males are also susceptible to breast cancer 
in the United States (4). The progression of breast cancer 
between an estrogen-dependent, non-metastatic phenotype 
and an estrogen-independent, invasive, metastatic phenotype 
are accompanied by chemoresistance (5). Treatment for 
breast cancer includes several approaches, including surgical 
and/or pharmacological approaches by estrogenic signaling in 
estrogen receptor-positive breast cancers (6). However, there is 
no targeted therapy for estrogen-independent breast cancer (7). 
Several studies have investigated combination therapies to 
improve the response to chemotherapy (8,9).
Continuous exposure of cancer cells to drugs leads to the 
development of a multidrug resistance (MDR) phenotype. The 
resistance of multiple chemotherapeutic drugs has been recog-
nized as a major contributor to the failure of cancer therapy 
and obstacle in the successful treatment of numerous types of 
malignancy (10). MDR occurs through several mechanisms, 
including increased adenosine triphosphate (ATP)-dependent 
efflux (11). The classical cellular mechanism of MDR involves 
efflux of the drug by various membrane transport proteins. 
ATP-binding cassette (ABC) transporters are a family of 
proteins, which mediate MDR via ATP‑dependent drug efflux 
pumps (12). Several transport proteins of the ABC superfamily 
have been characterized and include P-glycoprotein (P-gp, 
MDR-1; ABCB-1), multidrug resistance-associated protein-1 
(MRP-1; ABCC-1) and breast cancer resistance protein 
Salinomycin enhances doxorubicin-induced cytotoxicity in 
multidrug resistant MCF-7/MDR human breast cancer cells  
via decreased efflux of doxorubicin
KWANG-YOUN KIM1,2,  SANG-HUN KIM1,3,  SUN-NYOUNG YU1,  SUEL-KI PARK1,3,  HYEUN-DEOK CHOI1, 
HAK-SUN YU3,4,  JAE-HOON JI5,  YOUNG-KYO SEO2  and  SOON-CHEOL AHN1,3
1Department of Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, 
Gyeongsangnam-do 626-870; 2School of Life Sciences, Ulsan National Institute of Science and Technology, Ulsan 689-798;  
3Immunoregulatory Therapeutics Group in Brain Busan 21 Project; 4Department of Parasitology, 
Pusan National University School of Medicine, Yangsan, Gyeongsangnam-do 626-870; 5Genome Instability Research Center, 
Ajou University School of Medicine, Suwon, Gyeonggi-do 443-721, Republic of Korea
Received June 2, 2014;  Accepted March 16, 2015
DOI: 10.3892/mmr.2015.3633
Correspondence to: Professor Soon-Cheol Ahn, Department 
of Microbiology and Immunology, Pusan National University 
School of Medicine, Busandaehak-ro 49, Mulgeum-eup, Yangsan, 
Gyeongsangnam-do 626-870, Republic of Korea
E-mail: ahnsc@pusan.ac.kr
Professor Young-Kyo Seo, School of Life Sciences, Ulsan National 
Institute of Science and Technology, UNIST-gil 50, Eonyang-eup, 
Ulju-gun, Ulsan 689-798, Republic of Korea
E-mail: ykseo@unist.ac.kr
Key words: breast cancer, multidrug resistance, salinomycin, 
doxorubicin
KIM et al:  SALINOMYCIN ENHANCES DOXORUBICIN-INDUCED CYTOTOXICITY 1899
(BCRP; ABCG-2) which are overexpressed in chemoresistant 
cells (13).
Ionophore is a lipid-soluble molecule, which is usually 
produced by a variety of microbes to transport ions across 
biological membranes and increase the feeding efficiency of 
ruminant animals (14,15). Salinomycin is one of the mono-
carboxylic ionophores isolated from Streptomyces albus (16). 
Salinomycin has been demonstrated to cause the death of 
breast cancer stem cells (CSCs) more efficiently compared 
with the anticancer drug, paclitaxel  (17). Several reports 
have suggested that salinomycin induces apoptosis via cell 
cycle arrest and reactive oxygen species (ROS)-mediated 
mitochondrial pathways in a diversity of cancer cells (18,19). 
Salinomycin also triggers apoptosis by overcoming ABC 
transporter-mediated multidrug and apoptosis resistance in 
MDR cancer cells (20). Other reports have indicated that 
salinomycin induces apoptosis through the overexpression of 
B-cell lymphoma 2 and enhanced proteolytic activity, inde-
pendent of the p53 tumor suppressor protein in MDR cancer 
cells (18). Salinomycin-induced activation of autophagy, 
with concomitant generation of ROS and activation of endo-
plasmic reticulum stress has also been observed in human 
cancer cells (21,22). The effect of salinomycin on the death 
of CSCs and MDR types of cancer may demonstrate a 
novel class of anticancer agents. In the present study, it was 
hypothesized that salinomycin may act as a reverser of MDR 
and benefit patients receiving chemotherapy. The reversal 
effect of salinomycin was investigated and the underlying 
mechanism of action was evaluated in human breast cancer 
doxorubicin-sensitive MCF-7 and doxorubicin-resistant 
MCF-7/MDR cells.
Materials and methods
Reagents and antibodies. Salinomycin, doxorubicin and 
3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl-etrazolium brom
ide (MTT) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). The salinomycin and doxorubicin were dissolved 
in methanol (Samchun Pure Chemical, Pyeongtaek, Korea) 
and distilled water as 20 mM stock solutions, respectively. 
Antibodies for MDR-1, MRP-1 and β-actin were purchased 
from Enzo Life Sciences (Farmingdale, NY, USA) and Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), respectively. 
Gat-anti-mouseimmunoglobulin (Ig)G was purchased from 
Enzo Life Sciences. The ECL Western kit was purchased from 
GE Healthcare Bio-Sciences (Pittsburgh, PA, USA).
Cell lines and cell culture. The MCF-7 human breast 
cancer cells lines were obtained from American Type 
Culture Collection (Manassas, VA, USA). The MCF-7/MDR 
cell lines were generated through sequential exposure to 
increasing concentrations of doxorubicin (0.1-1 µM). The 
cells were maintained and cultured in Dulbecco's modified 
Eagle's medium (DMEM; WelGENE Inc., Daegu, Republic 
of Korea), supplemented with 10% fetal bovine serum 
(FBS; WelGENE Inc.), 100 U/ml penicillin and 100 µg/ml 
streptomycin (WelGENE Inc.) at a temperature of 37˚C in 
a humidified atmosphere with 5% CO2. Doxorubicin (1 µM) 
was added to the culture medium to maintain the MDR char-
acteristics of the MCF-7/MDR cells.
Cell viability analysis. The doxorubicin-sensitive MCF-7 
and doxorubicin-resistant MCF-7/MDR cells were seeded 
at a density of 1x104 cells/well into a 6-well plate. The cells 
were treated with doxorubicin (0.1-20 µM) and salino-
mycin (0.5-20 µM), either alone or in combination for 72 h. 
Subsequently, MTT solution (0.5 mg/ml) was added to the 
culture medium for a further 4 h incubation in a 37˚C and 5% 
CO2 atmosphere. The cells were then dissolved in dimethyl 
sulfoxide (Junsei Chemical Co., Tokyo, Japan). Colorimetric 
analysis was performed at 570 nm using an ELISA reader 
(VERSAmax microplate reader; Molecular Devices, Toronto, 
ON, Canada).
Intracellular accumulation of doxorubicin. Doxorubicin is a 
well‑known P‑gp substrate and is frequently used to treat breast 
cancer. In the present study, the MCF-7/MDR cells were seeded 
at a density of 5x104 cells in a glass-bottom dish. The cells were 
treated with 10 µM doxorubicin, alone or in combination with 
salinomycin (10-20 µM). Following 3 h incubation at 37˚C, the 
cells were washed three times with phosphate-buffered saline 
(PBS). To determine changes in the efflux of intracellular 
doxorubicin, a separate set of samples was incubated for 2 h 
at 37˚C in fresh medium without doxorubicin or salinomycin, 
as a control. The cells were visualized using a laser scanning 
confocal microscope (Olympus Fluoview FV1000; Olympus, 
Tokyo, Japan). To quantify the intracellular accumulation of 
doxorubicin, the cells were exposed to doxorubicin, alone or 
in combination with salinomycin for 3 h at 37˚C. The control 
samples were incubated without doxorubicin or salinomycin, 
or with salinomycin (10-20 µM) alone for 2 h at 37˚C. The cells 
were analyzed using flow cytometry (FACScalibur; Becton 
Dickinson, Franklin Lakes, NJ, USA) and the accumulation of 
doxorubicin was calculated using Cell Quest Pro software on 
Mac®OS 9 (Becton Dickinson).
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). The MCF-7/MDR cells were seeded into 60 cm2 cell 
culture dishes (1x106 cells). Following 24 h incubation at 37˚C, 
the cells were treated with salinomycin (10 or 20 µM) for 3 
and 6 h. Subsequently, the cells were harvested, and total RNA 
isolation was performed using a RiboEX_column Total RNA 
Purification kit (GeneAll, Seoul, Korea). RT‑qPCR amplifi-
cation was performed using primers for MDR1, MRP1 and 
GAPDH. The PCR primers were designed using the Primer3 
programs (http://frodo.wi.mit.edu) and the sequences were as 
follows: MDR1, forward 5'-ATATCAGCAGCCCACATCAT-3' 
and reverse 5'-GAAGCACTGGGATGTCCGGT-3'; MRP1, 
forward 5'-TGTGAGCTGGTCTCTGCCATA-3' and 
reverse 5'-CTGGCTCATGCCTGGACTCT-3' and GAPDH, 
forward 5'-GCCAAAAGGGTCATCATCTC-3' and reverse 
5'-GTAGAGGCAGGGATGATGTTC-3'. The PCR cycles 
were as follows: 94˚C for 5 min; 33 cycles at 94˚C for 1 min, 
58˚C for 1 min and 72˚C for 1 min; followed by 72˚C for 
10 min. For The RT‑qPCR was performed using low cycle 
numbers to avoid saturation, in triplicate samples.
Western blot analysis. The cell extracts were prepared by 
incubating the cells in lysis buffer, containing 150 mM NaCl, 
10 mM Tris (pH 7.4), 5 mM EDTA (pH 8.0), 1% Triton X-100, 
1 mM PMSF, 20 mg/ml aprotinin, 50 µg/ml leupeptin, 
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1 mM benzidine and 1 mg/ml pepstatin. Equal quantities 
of proteins (40 µg) were electrophoretically separated using 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) on an 8% gel, and were then transferred onto 
a polyvinylidenefluoride (PVDF) membrane (GE Healthcare 
Bio-Sciences). Following blocking with Tris-buffered saline 
with Tween 20 (TBS-T) containing 20 mM Tris (pH 7.4), 
150 mM NaCl and 0.1% Tween 20, with5% skim milk, 
the membranes were incubated with primary (MDR-1, 
MRP‑1 and β‑actin; 1:1,000; 4˚C overnight) and secondary 
(goat-anti-mouse; 1:5,000, 2 h at room temperature) anti-
bodies. The membranes were then washed with TBS-T buffer 
and visualized using enhanced chemiluminescence western 
blotting detection reagents. The density of each band was 
determined using a fluorescence scanner (LAS 3000; FujiFilm, 
Tokyo, Japan) and analyzed using Multi Gauge V3.0 software 
(FujiFilm).
Statistical analysis. The experiments were repeated at least 
three times with consistent results. Unless otherwise stated, the 
data are expressed as the mean ± standard deviation. Analysis 
of variance was used to compare the experimental groups 
with the control group, whereas comparisons among multiple 
groups were performed by Tukey’s multiple comparison test 
using Graphpad InStat V3.05. P<0.05 was considered to indi-
cate a statistically significant difference.
Results
Salinomycin sensitizes MCF‑7/MDR cells against doxorubicin. 
The effect of salinomycin on cytotoxicity was investigated 
using an MTT assay on the doxorubicin-sensitivite MCF-7 
or doxorubicin-resistant MCF-7/MDR cells. Following treat-
ment with various concentrations of doxorubicin for 72 h, the 
viability of cells against MCF-7 was reduced in a dose-depen-
dent manner. The half maximal inhibitory concentration 
of doxorubicin was <1 µM. By contrast, the MCF-7/MDR 
cells were highly resistant to doxorubicin (Fig. 1A). In addi-
tion, salinomycin significantly inhibited cell viability in the 
MCF-7 cells, however MCF-7/MDR cells exhibited only mild 
cytotoxicity compared with the MCF-7 cells when the cells 
were exposed to salinomycin alone, at the levels up to 20 µM 
(Fig. 1B). Salinomycin significantly enhanced the cytotoxicity 
of doxorubicin on the MCF-7/MDR cells in the dose-depen-
dent manner (Fig. 1C). In the presence of 10 µM salinomycin, 
the viabilities of these cells following 72 h treatment with 
10 or 20 µM doxorubicin were 19.4 and 18.2%, respectively, 
However, in the presence of 20 µM salinomycin, the viabilities 
at the same concentrations of doxorubicin were 12.4 and 8.1%, 
respectively. No significant effects of salinomycin on doxoru-
bicin cytotoxicity were observed on the MCF-7 cells (data not 
shown).
Salinomycin increases doxorubicin accumulation and 
decreases efflux in MCF‑7/MDR cells. The intracellular local-
ization and accumulation of doxorubicin in the MCF-7/MDR 
cells were observed using laser scanning confocal microscopy. 
Red fluorescence was observed in the cells (Fig. 2A) following 
treatment with 10 µM doxorubicin alone for 3 h. The fluo-
rescence observed following treatment with the combination 
of either 10 or 20 µM doxorubicin with salinomycin led to a 
marginal increase in the accumulation of doxorubicin, and 
was dependent on the salinomycin concentration (Fig. 2B 
Figure 1. Salinomycin enhances doxorubicin-mediated cytotoxicity in 
MCF-7/MDR cells. The cells were treated for 72 h. Cell viability was 
determined using an 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl-etrazolium 
bromide assay. (A) Doxorubicin-treated MCF-7 and MCF-7/MDR cells; 
(B) salinomycin-treated MCF-7 and MCF7/MDR cells; (C) combined treat-
ment of MCF-7 and MCF7/MDR cells with doxorubicin and salinomycin. All 
data are representative of at least three times independent experiments. and 
are expressed as the mean ± standard deviation. *P< 0.05. DOX, doxorubicin; 
MDR, multidrug resistance.
  A
  B
  C
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and C). At 2 h post-removal of doxorubicin and salinomycin, 
the fluorescence of the cytoplasmic signal in the control cells 
treated with doxorubicin alone was almost absent following its 
removal (Fig. 2D), however, the fluorescence remained evident 
in the cells pretreated with salinomycin (Fig. 2E and F). These 
results were consistent with the cell viability data, indicating 
that salinomycin induced the efflux of doxorubicin from the 
cells.
Salinomycin regulates the cellular uptake and efflux of 
doxorubicin in MCF‑7/MDR cells. To determine whether sali-
nomycin mediated the net uptake and efflux of doxorubicin 
in the MCF‑7/MDR cells, the flow cytometric intensities were 
analyzed. These results demonstrated significant increases, 
similar to those observed using confocal microscopy, in the 
net uptake of doxorubicin, and decreased efflux of doxorubicin 
by salinomycin (Fig. 3A and B). In the case of net uptake, at 
3 h post-treatment of the MCF-7/MDR cells with 10 µM doxo-
rubicin with either 10 or 20 µM salinomycin, the fluorescence 
signal intensities were 1.6- or 3.8-fold higher, respectively, 
compared with treatment with 10 µM doxorubicin alone. 
Following treatment with 20 µM doxorubicin with either 10 
or 20 µM salinomycin, the intensities were 1.7- and 4.9-fold 
higher, respectively, compared with treatment with 20 µM 
doxorubicin alone.
In terms of the eff lux of intracellular doxorubicin 
following removal of the drug from the culture media, the 
intracellular signal loss was significantly lower in the cells 
treated with a combination of doxorubicin and salinomycin, 
compared with that of the cells treated with doxorubicin 
alone (Fig. 3C and D). Compared with the signal prior 
to drug removal, the losses in intracellular doxorubicin 
2 h post-treatment were 75.1 and 69.3% following 3 h treat-
ment with 10 or 20 µM doxorubicin, respectively. The 
losses in intracellular doxorubicin were only 63.0 and 
46.1% following treatment with 10 or 20 µM salinomycin, 
compared with those observed following combined treat-
ment with salinomycin and 10 µM doxorubicin, respectively. 
In the cells treated with a combination of salinomycin and 
20 µM doxorubicin, the 63.3% loss of intracellular doxo-
rubicin was reduced to 37.5%. These results demonstrated 
that salinomycin enhanced doxorubicin-induced cytotoxicity 
by increasing the influx of doxorubicin and decreasing the 
efflux of doxorubicin in the MCF‑7/MDR cells.
Salinomycin regulates efflux and influx independently of the 
gene and protein expression levels of MDR1 and MRP1 in 
MCF‑7/MDR cells. To determine the mechanism underlying the 
reversal effect of salinomycin on the resistance of cancer cells, 
the present study examined the mRNA and protein expression 
levels of MDR1 and MRP1 in the MCF-7 and MCF-7/MDR 
cells. The mRNA and protein levels were estimated using 
RT‑qPCR and western blot analysis. Following treatment with 
salimycin (10 or 20 µM) for 3 and 6 h, no significant changes 
were detected in either the mRNA or protein expression levels 
(Fig. 4), compared with the cells not exposed to salinomycin. 
Figure 2. Salinomycin increases the accumulation and decreases the efflux of doxorubicin in MCF‑7/MDR cells. (A‑C) Confocal images of the accumulations 
of doxorubicin. The MCF-7/MDR cells were treated doxorubicin in the presence or absence of salinomycin for 3 h. (D-F) Confocal images of decreases of 
doxorubicin. The MCF-7/MDR cells were removed from doxorubicin and salinomycin treatment further and were observed after 2 h The cells were treated 
with either (A) doxorubicin alone (10 µM), (B) doxorubicin (10 µM) and salinomycin (10 µM), (C) doxorubicin (10 µM) and salinomycin (20 µM). (D) pretreat-
ment with doxorubicin alone; (E) pretreatment with doxorubicin and 10 µM salinomycin and (F) pretreatment with doxorubicin and 20 µM salinomycin. The 
original magnification of all images was x1,800, and the images were captured under the same microscope settings. All data are representative of at least three 
independent experiments.MDR, multidrug resistance.
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However, the MDR1 and MRP1 proteins were not detected 
in the MCF-7 cells. These results support the suggested that 
salinomycin did not affect the mRNA and protein expression 
levels of MDR1 and MRP1 mRNA and protein.
Discussion
MDR in cancer cells is a significant cause of failure in the 
chemotherapeutic treatment of several types of cancer (23). 
MDR involves cross-resistance to unassociated compounds by 
exposure to an anticancer agent (24). MDR cancer cells often 
exhibit elevated abilities of increased efflux (ATP‑dependent 
efflux pumps) or decreased influx. The development of MDR 
is mediated by different mechanisms, and conventional resis-
tance to anticancer drugs has been linked predominantly to 
the overexpression of ABC transporters, including P-gp, multi-
drug resistance-associated protein-1 and the breast cancer 
resistance protein (12).
Doxorubicin is an anthracycline antibiotic and is 
commonly used as an effective agent inthe treatment of 
several types of cancer, including bladder, breast and stomach 
cancer and multiple myeloma (25). Notably, the resistance 
of drugs, including doxorubicin, cisplatin and vinblastine, 
represents a major obstacle in the successful treatment of 
Figure 3. Salinomycin regulates the uptake and efflux of doxorubicin in MCF‑7/MDR cells. (A and B) Effects of salinomycin on the accumulation of doxoru-
bicin. The MCF-7/MDR cells were treated with doxorubicin, alone or in combination with salinomycin (10 or 20 µM) for 3 h. (C and D) Effects of salinomycin 
on the efflux of doxorubicin. The cells were removed from exposure to doxorubicin, but not salinomycin, for 2 h. (A and C) Flow cytometric analysis. 
1, untreated; 2, doxorubicin (10 µM); 3, doxorubicin  (10 µM) + salinomycin (10 µM); 4, doxorubicin (10 µM) + salinomycin (20 µM); 5, doxorubicin (20 µM); 
6, doxorubicin (20 µM) + salinomycin (10 µM); 7, doxorubicin (20 µM) + salinomycin (20 µM). All data are representative of at least three times independent 
experiment(B) Fold change in the intracellular fluorescent intensity. (D) Percentage loss of intracellular fluorescent intensity.. Data in B and D are expressed 
as the mean ± standard deviation (#P<0.05). MDR, multidrug resistance; Sal, salinomycin.
Figure 4. Salinomycin regulates efflux and influx independently of the expres-
sion of P‑glycoprotein in MCF‑7/MDR cells. (A) RT‑qPCR and (B) western 
blot analyses of the expression of MDR-1 and MRP-1  following treatment 
with salinomycin (10 or 20 µM) for 3 and 6 h. All data are representative of 
at least three times independent experiments. MDR, multidrug resistance.
  A   B
  C   D
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  B
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MDR cancer (26). There have been several reports on the 
use of doxorubicin in combination with certain other drugs, 
including fluorouracil and cyclophosphamide (27). The iden-
tification of novel combination drugs, which correlate with 
treatment response, has the potential to improve the success 
of MDR cancer therapy.
Salinomycin is an ionophore, which is used as a therapeutic 
antibacterial and coccidiostat (16). A previous study reported 
that salinomycin causes breast cancer stem cell death, by 
screening 16,000 different chemical compounds targeting 
cancer stem cell metastasis and relapse (17). In our previous 
study, salinomycin was observed to induce apoptosis via the 
ROS-mediated mitochondrial pathway (19). Other studies have 
supported these results in variety of cancer cells (23). It has 
also been demonstrated that salinomycin, as P-gp inhibitors, 
exhibit potent antiproliferative activity against MDR cancer 
cells (20).
The present study hypothesized that salinomycin may effec-
tively inhibit binding with P-gp and thus decrease the efflux of 
anticancer agents from the MDR cancer cells. To investigate 
this, doxorubicin-resistant MCF-7/MDR cells were treated 
with doxorubicin, alone or in combination with salinomycin, 
to assess cell viability. The results revealed the enhancement 
of salinomycin-mediated cytotoxicity in the MCF-7/MDR 
cells. This finding was consistent with those of the confocal 
microscope analysis, in which the doxorubicin fluorescent 
signals of the salinomycin-treated cells were higher compared 
with those in the cells treated with doxorubicin alone. In 
several previous studies, salinomycin has been revealed as a 
substrate with increased P-gp-dependent transport in MDR 
cancer cells, as evidenced through drug efflux assays in MDR 
cancer cell lines (28). Use of a conformational P-gp assay in a 
previous study provided evidence that the inhibitory effect of 
salinomycin on P-gp function may be mediated by the induc-
tion of ATP transporter conformational change (28). Using 
flow cytometric analysis, the present study confirmed that 
salinomycin significantly increased the net cellular uptake and 
decreased the cellular efflux of doxorubicin. Even 2 h following 
the removal of doxorubicin and salinomycin, the efflux rate 
of intracellular doxorubicin remained. Another important 
feature of salinomycin is that it facilitates bidirectional ion 
flux through the lipid barrier of membranes, acting as channel 
blockers to inhibit cell proliferation (29). A similar competitive 
mechanism has been observed in the reversal of MDR by P-gp 
inhibitors, including verapamil and cyclosporine A (30,31). In 
the present study, an efflux was examined using RT‑qPCR and 
western blot analysis, to determine whether this accumulation 
effect was directly associated with the gene and protein expres-
sion of MDR1 and MRP. The expression levels of MDR-1 and 
MRP-1 were not altered at either the mRNA or protein levels 
in the cells treated with salinomycin. These results indicated 
that salinomycin was mediated by its ability to promote the 
increased uptake and decreased efflux of doxorubicin in the 
MCF-7/MDR cells.
In analyzing the resistance of MCF-7/MDR cells treated 
with doxorubicin, the present study demonstrated that sali-
nomycin was a significant inhibitor, with a reversal effect on 
the resistance of cancer cells. When used in combination with 
chemotherapeutic agents in MDR cancer, salinomycin may 
have beneficial therapeutic effects.
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